Literature DB >> 18185061

Treatment of childhood obesity.

Naveen Uli1, Sumana Sundararajan, Leona Cuttler.   

Abstract

PURPOSE OF REVIEW: To provide an overview of treatments for childhood obesity, highlighting recent advances and recommendations. RECENT
FINDINGS: The three main treatment modalities are lifestyle interventions, medications, and bariatric surgery. Recent data support the short-term effectiveness of lifestyle interventions, and show that continued behavioral intervention increases the likelihood of a sustained effect for up to 2 years. New studies and regulatory decisions on medications for obesity (including orlistat, sibutramine, and metformin) are discussed. Emerging data suggest substantial weight loss after bariatric surgery in morbidly obese adolescents but also indicate adverse effects. An expert panel recently provided guidelines that alter definitions of obesity and offer a framework for obesity management. These guidelines are compared with others, and integrated recommendations presented.
SUMMARY: While primary prevention of childhood obesity is important, broadly effective methods to do so are not yet available. Given the large population of obese children and the risks they face, an emphasis on treatment is also critical. We suggest a staged approach, emphasizing early intervention and lifestyle changes. We also suggest limiting bariatric surgery to selected adolescents in Institutional Review Board-approved research studies. Health-policy interventions can facilitate both prevention and treatment of childhood obesity.

Entities:  

Mesh:

Year:  2008        PMID: 18185061     DOI: 10.1097/MED.0b013e3282f41d6a

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  10 in total

Review 1.  Pharmacotherapy in pediatric obesity: current agents and future directions.

Authors:  Abigail B Wald; Naveen K Uli
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

2.  Why Bariatric surgery should be given high priority: an argument from law and morality.

Authors:  Karl Persson
Journal:  Health Care Anal       Date:  2014-12

3.  Obesity as a Socially Defined Disease: Philosophical Considerations and Implications for Policy and Care.

Authors:  Bjørn Hofmann
Journal:  Health Care Anal       Date:  2016-03

4.  IMPACT: a multi-level family and school intervention targeting obesity in urban youth.

Authors:  Shirley M Moore; Elaine A Borawski; Leona Cuttler; Carolyn E Ievers-Landis; Thomas E Love
Journal:  Contemp Clin Trials       Date:  2013-09-02       Impact factor: 2.226

5.  A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.

Authors:  Hasan Rezvanian; Mahin Hashemipour; Roya Kelishadi; Naser Tavakoli; Parinaz Poursafa
Journal:  World J Pediatr       Date:  2010-11-16       Impact factor: 2.764

Review 6.  Ethical issues of obesity surgery--a health technology assessment.

Authors:  Samuli I Saarni; Heidi Anttila; Suoma E Saarni; Pertti Mustajoki; Vesa Koivukangas; Tuija S Ikonen; Antti Malmivaara
Journal:  Obes Surg       Date:  2011-09       Impact factor: 4.129

7.  Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy.

Authors:  Z S Daniels; T G Nick; C Liu; A Cassedy; T A Glauser
Journal:  Neurology       Date:  2009-05-27       Impact factor: 9.910

8.  Pharmacological approaches for management of child and adolescent obesity.

Authors:  Amar Kanekar; Manoj Sharma
Journal:  J Clin Med Res       Date:  2010-05-19

Review 9.  Bariatric surgery for obese children and adolescents: a review of the moral challenges.

Authors:  Bjørn Hofmann
Journal:  BMC Med Ethics       Date:  2013-04-30       Impact factor: 2.652

10.  METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study.

Authors:  Marloes P van der Aa; Marieke A J Elst; Edgar G A H van Mil; Catherijne A J Knibbe; Marja M J van der Vorst
Journal:  Trials       Date:  2014-06-05       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.